• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Companies that Ward Off ESG and Reputation Crises See Value Surge

    3/8/22 8:00:00 AM ET
    $APO
    $CVS
    $FB
    $JNJ
    Investment Managers
    Finance
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $APO alert in real time by email

    PITTSBURGH, March 8, 2022 /PRNewswire-PRWeb/ -- Companies with ESG and reputational risk protection strategies have seen their stock prices rise 5% above the market within two weeks of a reputational challenge, and that premium is almost double for companies that have publicly shared and validated those strategies.

    The study, by Steel City Re, an ESG and reputation insurer, also found that stock prices of firms that managed, validated and publicized ESG and reputation risk management strategies on average gained 9.3% over the subsequent seven months after a precipitating event, while firms in which such processes were in assumed by shareholders to be in place gained 4.3%. Companies that failed to institute, validate, and communicate risk management strategies lost 13.2% of their stock value over those seven-month periods, and they underperformed their peers by an average of 23.3%.

    "Investors appear to reward firms that actively manage reputational risks as operational strategies and not just potential PR problems," said Nir Kossovsky, Steel City Re's CEO. "Our study makes the case for ESG-focused firms to take a more structured, substantive and comprehensive approach to risk governance and management."

    "The data show that instituting, validating, and communicating risk management strategies can both fulfill the goals of stakeholder-centrism and meet shareholder expectations," he added.

    Illustrative highlights include:

    • Johnson & Johnson (NYSE:JNJ) outperformed the market by 16% ($1.7bn) when its much publicized strategic supply chain security and product safety processes were proven effective in 1986.
    • Rolls Royce (OTC:RYCEY), whose board defined its risk governance mission as protecting the reputation, viability, and profitability of the firm, outperformed the market by 14.9% ($3.4bn) after it proved the quality of its safety controls throughout its supply chain in 2011.
    • Apollo Global Management (NYSE:APO) outperformed the market by 16.6% ($1.9bn) after it announced an ESG-focused governance reorganization and presented in 2021 and independent validation of a 3-year investment in reputation risk management.
    • CVS (NYSE:CVS) outperformed the market by 9.3% ($8.6bn) when, presciently anticipating the ESG movement, it pursued an ethical innovative strategy that shunned tobacco products in 2014. It outperformed rivals Walgreens (NYSE:WBA) and Rite Aid (NYSE:RAD) by 16.6% and 24.8% respectively.
    • Apple (NADQ:AAPL) outperformed the market by 24% ($505bn) after introducing innovative ethical privacy features that addressed a critical ESG concern in the technology sector in 2021. It outperformed Meta (NYSE:FB), facing a range of privacy challenges, by 34.9%.

    About the Study

    The Steel Re study looked at seven firms that took direct action to publicize their reputation risk management and governance, 20 firms whose protection strategies were in assumed by shareholders to be in place because of their response to external events, 20 firms whose strategies were shown to be insufficient over seven months, and from among these, 22 firms whose reputational impairment and value losses were measured against peer competitors.

    The reputational challenges were all public events over the past 15 years supplemented by iconic cases of Johnson & Johnson's two Tylenol-related safety events of the 1980's. Individual gains and losses were calculated after normalizing for changes in the S&P500, and the date for ESG and reputational events was determined by a marked surge in stakeholder interest as explored in a related Steel City Re white paper.

    About Steel City Re

    Steel City Re provides parametric ESG insurance, reputational insurance and helps guide companies' boards and senior leadership in developing enhanced risk governance and management practices. Its underwriting model is supported by more than 7.3 million measures of reputational value and traditional financial metrics that also fuel ESG-focused hedge fund strategies. Its risk governance and management models are informed by principles of behavioral economics.

    Media Contact

    Desiree Niccoli, Steel City Re, 412-804-8649, [email protected]

    Steve Alschuler, Steel City Re, 917-647-2151, [email protected]

     

    SOURCE Steel City Re

    Get the next $APO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APO
    $CVS
    $FB
    $JNJ

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    10/20/2025$203.00Neutral → Outperform
    Daiwa Securities
    CVS Health Corporation
    $CVS
    10/14/2025$91.00Buy
    Goldman
    Apollo Global Management Inc. (New)
    $APO
    10/3/2025$132.00Market Perform
    BMO Capital Markets
    Johnson & Johnson
    $JNJ
    10/3/2025$212.00Equal Weight → Overweight
    Wells Fargo
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    CVS Health Corporation
    $CVS
    8/18/2025$79.00Neutral → Buy
    UBS
    CVS Health Corporation
    $CVS
    8/14/2025$82.00Neutral → Outperform
    Robert W. Baird
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    More analyst ratings

    $APO
    $CVS
    $FB
    $JNJ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Johnson & Johnson upgraded by Daiwa Securities with a new price target

    Daiwa Securities upgraded Johnson & Johnson from Neutral to Outperform and set a new price target of $203.00

    10/20/25 8:00:27 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Goldman initiated coverage on CVS Health with a new price target

    Goldman initiated coverage of CVS Health with a rating of Buy and set a new price target of $91.00

    10/14/25 8:48:20 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    BMO Capital Markets initiated coverage on Apollo Global Management with a new price target

    BMO Capital Markets initiated coverage of Apollo Global Management with a rating of Market Perform and set a new price target of $132.00

    10/3/25 8:36:49 AM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

    For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

    9/12/23 10:44:21 AM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    July 21, 2023 - FDA Roundup: July 21, 2023

    For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

    7/21/23 4:02:23 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

    For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

    5/5/22 4:51:11 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Innovative Medicine, R&D Reed John C exercised 21,721 shares at a strike of $157.92 and sold $4,185,793 worth of shares (21,721 units at $192.71) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    10/20/25 7:13:56 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: New insider Capozzi Heidi B claimed ownership of 5 shares (SEC Form 3)

    3/A - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:06:56 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile

    Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch to a new oral therapy with equivalent efficacy and a favorable safety profile Results show 50.5% of adult psoriasis patients eligible for systemic therapy and 47.5% of dermatology providers would prefer oral treatment over topicals or injectables SPRING HOUSE, Pa., Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced findings from the U.S. dataset from the global ENCOMPASS study evaluating patient and healthcare provider (HCP) perspectives on barriers and unmet needs in psoriasis care. The results, presented

    10/27/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

    Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only IL-23 inhibitor to demonstrate durable endoscopic and clinical remission with a fully subcutaneous regimen in moderately to severely active Crohn's disease PHOENIX, Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new 96-week data from the long-term extensions (LTE) of the Phase 3 GRAVITI, GALAXI 2 and GALAXI 3 studies, which show the durability of TREMFYA® (guselkumab) in adults with moderately to severely active Crohn's disease (CD) at two years.1 These findings are among 23 Johnson & Johnson abstracts being pre

    10/27/25 7:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis

    Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus placebo in the Phase 2b ANTHEM-UC study Results support Phase 3 clinical development of icotrokinra, a first-in-class targeted oral peptide that precisely blocks the IL-23 receptor, in both moderately to severely active ulcerative colitis and Crohn's disease PHOENIX, Oct. 27, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced Week 28 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that precisely blocks the IL-23 recepto

    10/27/25 7:30:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APO
    $CVS
    $FB
    $JNJ
    SEC Filings

    View All

    SEC Form 10-Q filed by Johnson & Johnson

    10-Q - JOHNSON & JOHNSON (0000200406) (Filer)

    10/22/25 4:04:17 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

    8-K - JOHNSON & JOHNSON (0000200406) (Filer)

    10/14/25 7:22:58 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by CVS Health Corporation

    8-K - CVS HEALTH Corp (0000064803) (Filer)

    9/22/25 4:19:42 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief People Officer Capozzi Heidi B bought $4,589 worth of shares (80 units at $57.36) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    10/14/25 7:08:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Sansone Guy P bought $100,009 worth of shares (1,570 units at $63.70), increasing direct ownership by 15% to 12,007 units (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    6/9/25 8:22:46 AM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

    4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

    4/29/25 8:49:21 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    $APO
    $CVS
    $FB
    $JNJ
    Leadership Updates

    Live Leadership Updates

    View All

    CVS Health Helps Improve Access to More Affordable Fertility Treatments

    WOONSOCKET, R.I., Oct. 16, 2025 /PRNewswire/ -- CVS Health (NYSE:CVS) today announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization (

    10/16/25 5:09:00 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Apollo Names Eiji Ueda Head of Asia Pacific as Firm Marks 20 Years in Region

    TOKYO and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:APO) today announced Mr. Eiji Ueda has been named a Partner and Head of Asia Pacific, succeeding Matt Michelini. Michelini, who has spearheaded Apollo's rapid expansion across the region since his appointment in 2022, will remain in region to oversee Ueda's transition before assuming broader leadership responsibilities with the firm next year. Ueda joins Apollo with demonstrated investment expertise and a nuanced understanding of Asia's evolving needs. He most recently served as Chief Investment Officer of Japan's Government Pension Investment Fund (GPIF), one of the largest institutional investors globally, where he led a

    10/15/25 8:05:00 PM ET
    $APO
    Investment Managers
    Finance

    Shutterfly Names Emily Whittaker Chief Executive Officer

    Sally Pofcher, Shutterfly's current CEO, to Transition After Leading Transformation and Setting Stage for Further Growth Shutterfly, the leading e-commerce company for personalized products and custom design, announced its current CEO, Sally Pofcher, will transition from the role of Chief Executive Officer as part of a planned succession. Emily Whittaker of VistaPrint will assume the role later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006485281/en/Emily Whittaker, former VistaPrint Executive Vice President of North America & Head of Global Marketing, assumes the role of Shutterfly CEO later this month. Sal

    10/6/25 1:00:00 PM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Financials

    Live finance-specific insights

    View All

    KDP Discusses Strategy, Leadership and Financing for Upcoming Transformational Transactions

    At Investor Day, outlines conviction in the JDE Peet's acquisition and robust plans to execute integration and separation Announces capital-efficient $7 billion strategic investment co-led by Apollo and KKR to reduce projected net leverage at acquisition close; sets targeted capital structure for each company at separation BURLINGTON, Mass. and FRISCO, Texas, Oct. 27, 2025 /PRNewswire/ -- Today, Keurig Dr Pepper (NASDAQ:KDP) announced new details about strategy, leadership and financing related to the acquisition of JDE Peet's and subsequent planned separation into two independent companies. Members of KDP's Board of Directors and management team will speak to these announcements this morni

    10/27/25 7:18:00 AM ET
    $APO
    $KDP
    $KKR
    Investment Managers
    Finance
    Beverages (Production/Distribution)
    Consumer Staples

    Sotherly Hotels Inc. to be Acquired by Joint Venture Backed by Kemmons Wilson Hospitality Partners and Ascendant Capital Partners

    WILLIAMSBURG, Va., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Sotherly Hotels Inc. (NASDAQ:SOHO) ("Sotherly" or the "Company") today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with a joint venture led and sponsored by affiliates of Kemmons Wilson Hospitality Partners, LP ("KWHP"), with Ascendant Capital Partners LP ("Ascendant") serving as a strategic joint venture partner (collectively, the "Joint Venture"), under which the Joint Venture entity, KW Kingfisher LLC, will acquire all outstanding shares of Sotherly common stock for $2.25 per share in cash (the "Merger Consideration"). The Merger Consideration represents a premium of 152.7% to the Company

    10/27/25 6:30:00 AM ET
    $APO
    $SOHO
    Investment Managers
    Finance
    Real Estate Investment Trusts
    Real Estate

    BLP Strengthens Southern California Position with 450,000-SF, Two-Building Industrial Acquisition in City of Industry

    The fully leased portfolio offers valuable space in a supply-constrained market and underscores BLP's commitment to high-quality logistics assets. Bridge Logistics Properties ("BLP"), subsidiary of Bridge Investment Group Holdings LLC (together with its affiliates, "Bridge"), today announced the acquisition of a two-building, 450,000-square-foot industrial portfolio in the City of Industry, California. The transaction builds on BLP's momentum in key infill markets and supports its long-term growth strategy across Southern California. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251023123040/en/BLP Acquires Two Industrial Bui

    10/23/25 10:00:00 AM ET
    $APO
    Investment Managers
    Finance

    $APO
    $CVS
    $FB
    $JNJ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by CVS Health Corporation

    SC 13G - CVS HEALTH Corp (0000064803) (Subject)

    11/13/24 1:00:57 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

    SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

    10/18/24 12:45:41 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

    SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

    8/20/24 4:05:58 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples